

INTRODUCTION	xix
STUDY GOALS AND OBJECTIVES	xix
REASONS FOR DOING THIS STUDY	xix
CONTRIBUTIONS TO THE STUDY AND FOR WHOM	xix
SCOPE AND FORMAT	xx
METHODOLOGY	xx
INFORMATION SOURCES	xx
ABOUT THE AUTHOR	xxi
RELATED BCC WORK CREDENTIALS	xxi
OTHER RELATED BCC REPORTS	xxi
BCC ONLINE SERVICES	xxi
DISCLAIMER	xxi
 SUMMARY	 xxiii
<i>SUMMARY TABLE U.S. MARKET FORECAST FOR IN VITRO TOXICITY TESTING BY TECHNOLOGY, THROUGH 2011 (\$ MILLIONS)</i>	 XXIV
<i>SUMMARY FIGURE SEGMENTATION BY TECHNOLOGY APPROACH, 2004- 2011 (\$ MILLIONS)</i>	 XXV
 OVERVIEW	 1
INTRODUCTION TO TOXICOLOGY	2
BASIC PRINCIPLES OF TOXICOLOGY	2
AGENTS OF TOXICOLOGY AND THEIR CLASSIFICATION	3
<i>TABLE 1 TYPES OF SYSTEMIC TOXICITY</i>	4
FACTORS INFLUENCING TOXICITY OF A SUBSTANCE	4
Means of Exposure	5
Dose Expressions and Dose Response Functions	5
<i>TABLE 2 TYPE OF DOSES</i>	6
Disposition of Toxicants	6
DEVELOPMENT OF TOXICOLOGY	7
<i>FIGURE 1 CLASSICAL APPROACH</i>	7
DEVELOPMENT OF TOXICOLOGY (CONTINUED)	8
<i>FIGURE 2 ALTERNATIVE APPROACH</i>	9
CLASSES OF TESTS	9
DISTINGUISHED BY SPECIFIC END POINT	10
Reproductive and Developmental Toxicity	10
Screening Assays -Level Reproductive-Toxicity	10
Prenatal Developmental-Toxicity Study and Teratology Study	11
Generational Tests	11
Reproductive Assessment by Continuous Breeding	11
Neurotoxicity	12

Immunotoxicity	12
Genotoxicity	13
Gene or Point Mutations	13
Chromosomal Aberrations	14
DNA Damage.....	14
Carcinogenicity	14
TABLE 3 <i>IN VITRO TESTS FOR DIFFERENT TOXICITY END POINTS</i>	15
Acute Toxicity Testing.....	15
LD50	15
TABLE 4 <i>EPA ACUTE-TOXICITY CATEGORIES</i>	16
Chronic Toxicity Testing.....	16
Sub-Chronic or Repeated-Dose Toxicity Testing.....	17
Subacute Testing	18
TYPES OF TOXICOLOGY.....	19
TABLE 5 <i>CLINICAL TOXICOLOGY IN THE HOSPITAL SETTING</i>	19
TABLE 6 <i>FORENSIC TOXICOLOGY, APPLICATION IN THE MEDICAL</i>	
<i>EXAMINER'S OFFICE</i>	19
TABLE 7 <i>INDUSTRIAL TOXICOLOGY</i>	20
TABLE 8 <i>PRODUCT DEVELOPMENT TOXICOLOGY, IN THE</i>	
<i>BUSINESS/CORPORATE ARENA</i>	20
TABLE 9 <i>REGULATORY TOXICOLOGY IN INDUSTRY AND</i>	
<i>GOVERNMENT SETTINGS</i>	20
TECHNICAL OVERVIEW	21
TOXICITY TESTING STRATEGIES.....	21
TABLE 10 <i>FOCAL POINTS FOR ALTERNATIVE APPROACHES IN</i>	
<i>TOXICITY TESTING</i>	22
TYPES OF TOXICITY-TESTING STRATEGIES	23
TABLE 11 <i>DIFFERENT APPROACHES TO IN VITRO TESTS</i>	24
ALTERNATIVE TOXICOLOGY METHODS FOR DIFFERENT	
TOXICITY CATEGORIES	24
Cytotoxicity	24
<i>In Vitro</i> Tests for Cellular Toxicity and Other End points	25
TABLE 12 <i>VALIDATED ASSAYS FOR CYTOTOXICITY EVALUATION</i>	26
TABLE 12 <i>(CONTINUED)</i>	27
Specific Target End Point Toxicity	27
TABLE 13 <i>COMPARISON OF IN VITRO SYSTEMS FOR HEPATOTOXICITY</i>	
<i>STUDIES</i>	28
Ocular Toxicity	29
<i>In Vitro</i> Methods for Ocular Irritation	29
BCOP.....	29
HET-CAM	30
ICE Test	31
The IRE Test.....	31
TABLE 14 <i>COMPARISON OF ALTERNATIVE IN VITRO APPROACHES TO THE</i>	
<i>CONVENTIONAL MODEL</i>	32

EpiOcular	33
<i>In Vitro</i> Tests for Dermal Corrosivity.....	33
CORROSITEX	33
TER ASSAY	34
Frog Embryo Teratogenesis Assay-Xenopus (FETAX)	
Test Assay for Developmental Toxicity	34
<i>In Vitro</i> Endocrine Screening Disruptor Assays.....	34
The Local Lymph Node Assay (LLNA)	35
<i>In Vitro</i> 3T3 NRU Phototoxicity Test.....	35
<i>In Vitro</i> Tests for Pyrogenicity	36
VALIDATION.....	37
SIGNIFICANCE OF VALIDATION	37
SIGNIFICANCE OF VALIDATION (CONTINUED)	38
SIGNIFICANCE OF VALIDATION (CONTINUED)	39
FIGURE 3 FLOWCHART ILLUSTRATING THE IMPORTANCE OF VALIDATION.....	40
SIGNIFICANCE OF VALIDATION (CONTINUED)	41
SIGNIFICANCE OF VALIDATION (CONTINUED)	42
CHALLENGES FACING VALIDATION.....	43
LOGISTICAL SIMPLIFICATION OF DATA GENERATION AND	
AVAILABILITY	43
LACK OF AVAILABLE GUIDANCE ON TESTING APPROACHES	
VIS-À-VIS TESTING METHODS	44
UNSTEADY FLOW OF NEW TEST METHODS FOR VALIDATION	44
UNSTEADY FLOW (CONTINUED)	45
COMPANY PROFILES	46
ACCELRY'S SOFTWARE, INC.....	46
BIO-RAD LABORATORIES	47
BIORELIANCE INVITROGEN BIOSERVICES.....	47
CEETOX, INC.	48
COVANCE, INC.	48
GENEGO, INC.....	49
GENE LOGIC, INC.	49
GENE LOGIC, INC. (CONTINUED)	50
HTG, ARIZONA	51
ICONIX BIOSCIENCES, INC.	51
IN VITRO INTERNATIONAL	52
IN VITRO TECHNOLOGIES.....	52
MATTEK CORPORATION	53
MATTEK CORPORATION (CONTINUED)	54
MOLECULAR TOXICOLOGY, INC.	55
TECAN GROUP AG	55
XENOBIOTIC DETECTION SYSTEMS (XDS)	56
XENOMETRIX.....	57

MARKETS BY TECHNOLOGY	58
MARKETS BY TECHNOLOGY	58
TABLE 15 SEGMENTATION FOR ALTERNATIVE APPROACHES TO TOXICITY (PREDICTIVE TOXICITY TESTING)	59
SIGNIFICANT TECHNOLOGY DEVELOPMENTS	59
ALTERNATIVES METHODS IN TOXICOLOGY TESTING	59
3R Approach	59
TABLE 16 ADVANTAGES AND LIMITATIONS OF IN VITRO ORGANOTYPIC CONSTRUCTS	60
Reduction Alternative	60
Replacement Alternative	60
Refinement	61
Use of Alternative Species	61
OVERVIEW OF HIGH ENABLING TECHNOLOGIES	61
Toxicogenomics	61
Toxicogenomics (Continued)	62
TABLE 17 MAJOR COMPANIES IN TOXICOGENOMICS RESEARCH	63
Microarrays	64
Proteomics	64
Metabolomics	64
Bioinformatics	65
Computational Toxicology	65
Structure-Activity Relationships	65
Physiologically Based Pharmacokinetic Models (PBPK)	66
TABLE 18 APPLICATIONS OF PBPK MODELS	67
Biologically Based Dose-Response (BBDR) Models	67
Computational Approaches to Predicting Metabolic Fate	68
TABLE 19 COMMERCIALY AVAILABLE SYSTEMS FOR METABOLIC FATE PREDICTION	69
Future Uses of Computational Toxicology	69
<i>In Silico</i> Modeling	70
Technology Hurdles	70
Standardization of Data Sets: A Critical Barrier Needing Immense Attention	71
Dynamic Complex Biological Processes	71
Statistical Techniques Face Some Impediments	71
Toxicogenomics Techniques Face Economic Realities	72
TABLE 20 CHALLENGES FACED BY TOXICOGENOMICS	72
TABLE 21 STRENGTHS, WEAKNESSES, OPPORTUNITIES, AND THREATS (SWOT) TO OMICS TECHNOLOGIES	72
TABLE 21 (CONTINUED)	73
ROADMAP FOR THE FUTURE	73
Roadmap for the Future (Continued)	74
REVENUE FORECASTS BY TECHNOLOGY	75

REVENUE FORECASTS BY TECHNOLOGY	75
REVENUE FORECASTS BY ... (CONTINUED)	76
OBSERVATIONS	77
TABLE 22 U.S. IN VITRO TOXICITY TESTING MARKETS: CONTRIBUTION BY TECHNOLOGY	77
TABLE 23 U.S. MARKET FORECAST FOR IN VITRO TOXICITY TESTING BY TECHNOLOGY, THROUGH 2011 (\$ MILLIONS)	78
FIGURE 4 U.S. IN VITRO TOXICITY TESTING MARKET FORECAST, NON- MECHANISTIC VS. MECHANISTIC APPROACH, 2006 AND 2011 (\$ MILLIONS)	78
FIGURE 5 ESTIMATED CONTRIBUTION OF TECHNOLOGY SEGMENTS FOR THE U.S. IN VITRO TOXICITY TESTING MARKETS (%)	79
 PATENT ANALYSIS	 80
TABLE 24 U.S. PATENTS ISSUED FOR IN VITRO TOXICITY RESEARCH	80
TABLE 24 (CONTINUED)	81
TABLE 24 (CONTINUED)	82
TABLE 25 SEGMENTATION OF PATENTS BY ORGANIZATIONS	82
TABLE 26 SEGMENTATION OF PATENTS BY TECHNOLOGIES	83
PATENT ABSTRACTS PERTAINING TO TOXICOLOGY SCREENING	83
UNIVERSITEIT GENT (U.S. PATENT NUMBER: 6,436,630)	83
ANTI-CANCER, INC. (U.S. PATENT NUMBER: 6,399,380)	83
WISCONSIN ALUMNI RESEARCH FOUNDATION (U.S. PATENT NUMBER: 6,150,126).....	84
PHARMACIA & UPJOHN COMPANY (U.S. PATENT NUMBER: 6,998,249).....	84
LYNX THERAPEUTICS, INC. (U.S. PATENT NUMBER: 6,228,589)	84
THE PROCTER & GAMBLE COMPANY (U.S. PATENT NUMBER: 6,020,148).....	84
LION BIOSCIENCE AG (U.S. PATENT NUMBER: 6,996,473).....	85
U.S. Patent Number: 6,542,858	85
TRELLIS BIOSCIENCE, INC. (U.S. PATENT NUMBER: 7,060,447)	85
PHYLONIX PHARMACEUTICALS, INC. (U.S. PATENT NUMBER: 6,299,858).....	85
BRISTOL-MYERS SQUIBB COMPANY (U.S. PATENT NUMBER: 7,041,501).....	86
OTSUKA PHARMACEUTICAL CO., LTD. (U.S. PATENT NUMBER: 7,018,806).....	86
EXONHIT THERAPEUTICS S.A. (U.S. PATENT NUMBER: 6,881,571).....	86
 INDUSTRY COMPETITIVENESS.....	 87
INDUSTRY TRENDS FOR <i>IN VITRO</i> TOXICITY TESTING.....	87
INTRODUCTION.....	87
MARKET OVERVIEW.....	88
Market Lifecycle	88

<i>FIGURE 6 U.S. IN VITRO TOXICITY TESTING MARKETS: MARKET LIFECYCLE, 2006</i>	89
Segmentation	90
INDUSTRY STRUCTURE	90
INDUSTRY STRUCTURE (CONTINUED)	91
<i>TABLE 27 COMPANIES PROVIDING TOXICITY TESTING SERVICES</i>	92
<i>TABLE 28 IN VITRO TOXICITY TESTING SUPPLIERS (DEDICATED/NON-DEDICATED)</i>	93
<i>TABLE 28 (CONTINUED)</i>	94
<i>TABLE 29 U.S. IN VITRO TOXICITY TESTING MARKET FORECASTS, THROUGH 2011 (\$ MILLION)</i>	95
COMPETITIVE FRAMEWORK	95
<i>FIGURE 7 COMPETITIVE FRAMEWORK</i>	96
Pricing Trends	96
International Scenario	97
<i>TABLE 30 GLOBAL MARKET FORECASTS AND SHARES OF IN VITRO TOXICITY TESTING, THROUGH 2011 (\$ MILLION)</i>	98
<i>TABLE 31 EUROPEAN IN VITRO TOXICITY TESTING MARKET FORECASTS AND SHARES, THROUGH 2011 (\$ MILLION)</i>	99
International Scenario (Continued)	100
International ... (Continued)	101
<i>TABLE 32 EUROPEAN IN VITRO TOXICITY TESTING MARKET FORECASTS BY INDUSTRY, THROUGH 2011 (\$ MILLIONS)</i>	102
MARKET TRENDS BY INDUSTRY SECTOR FOR <i>IN VITRO</i> TOXICITY TESTING	103
COSMETICS AND HOUSEHOLD PRODUCTS	103
COSMETICS AND ... (CONTINUED)	104
<i>TABLE 33 COSMETIC MANUFACTURERS ADOPTING IN VITRO TESTING MEASURES</i>	105
<i>TABLE 33 (CONTINUED)</i>	106
PHARMACEUTICAL INDUSTRY OUTLOOK	106
<i>TABLE 34 PHARMACEUTICAL COMPANIES INVOLVED IN TOXICOGENOMICS RESEARCH</i>	107
DRUG DISCOVERY AND DEVELOPMENT OVERVIEW	108
NEW PRODUCT DEVELOPMENTS AND ITS SIGNIFICANCE IN THE BIOPHARMACEUTICAL SECTOR	109
<i>FIGURE 8 U.S. PHARMACEUTICAL R&D EXPENDITURE, 1970–2005</i>	110
<i>FIGURE 9 R&D EXPENDITURES, TOTAL AND AS A PERCENTAGE OF REVENUE, 1965–2003</i>	110
The Need for Predictive Toxicity	111
Adverse Drug Reactions Fueling the Need for Predictive Toxicity	111
Typical Reasons for Drug Attrition	112
<i>TABLE 35 MAJOR CAUSES OF DRUG ATTRITION (%)</i>	112
<i>FIGURE 10 DRUG R&D PROCESS</i>	112

<i>TABLE 36 STAGES OF DRUG DEVELOPMENT AND PERCENTAGE SHARES OF R&D EXPENDITURE (%)</i>	113
<i>FIGURE 11 REASONS FOR DRUG ATTRITION AT THE LEAD OPTIMIZATION PHASE</i>	113
Typical Reasons for Drug Attrition (Continued).....	114
Typical Reasons ... (Continued).....	114
<i>TABLE 37 KEY FEATURES TO GENERATE LEAD COMPOUNDS</i>	115
<i>TABLE 38 SWOT ANALYSIS FOR THE IN VITRO TOXICITY TESTING MARKET IN THE PHARMACEUTICAL INDUSTRY, 2006</i>	116
<i>TABLE 39 TOP PHARMACEUTICAL MANUFACTURERS' CHALLENGES AND THEIR IMPACT, 2006–2011</i>	117
<i>TABLE 40 IMPACT OF END USER CHALLENGES, 2006–2011</i>	117
FOOD INDUSTRY.....	118
FOOD INDUSTRY (CONTINUED).....	119
<i>TABLE 41 DISADVANTAGES OF IN VITRO SYSTEMS SUCH AS INTACT CELLS, TISSUE SLICES, AND ORGAN CULTURES</i>	120
TOXICITY TESTING STRATEGIES.....	121
Federal Insecticide, Fungicide, and Rodenticide Act Testing Program	121
<i>TABLE 42 BATTERY OF TESTS REQUIRED BY EPA FOR NEW PESTICIDE CHEMICALS</i>	122
Microbial Pest-Control Agents Testing Program	123
FDA Testing Strategies for Food Additives	123
<i>TABLE 43 TOXICITY TESTS FOR MICROBIAL PEST-CONTROL AGENTS</i>	123
<i>TABLE 44 CONCERN LEVELS FOR DIRECT FOOD ADDITIVES</i>	124
<i>TABLE 45 TESTING REQUIREMENTS FOR DIRECT AND INDIRECT FOOD ADDITIVES</i>	125
CHEMICALS INDUSTRY	126
THE HIGH PRODUCTION VOLUME CHALLENGE PROGRAM (HPV).....	126
Shortcomings of the HPV Implementation	127
Conclusion.....	128
REACH PROGRAM	128
Toxicogenomics and Its Potential to Assess Environmental Carcinogens.....	129
<i>TABLE 46 POTENTIAL OF TOXICOGENOMICS FOR ENVIRONMENTAL CARCINOGENS</i>	129
TOXICITY-TESTING STRATEGIES FOR SCREENING OF INDUSTRIAL CHEMICALS	129
The Toxic Substances Control Act and the High-Production-Volume Chemical Testing Program.....	130
<i>TABLE 47 BASIC SCREENING INFORMATION DATA SET TESTING BATTERY</i>	130
TESTING STRATEGIES FOR SCREENING CHEMICALS	
ADDRESSING SPECIFIC SYSTEM END POINTS	131
EPA Endocrine-Disruptor Testing Strategy	131

<i>TABLE 48 DIFFERENT CATEGORIES OF CHEMICALS TO PRIORITIZE TESTING METHODS</i>	132
<i>TABLE 49 ENDOCRINE-DISRUPTOR SCREENING TESTS</i>	132
OECD Endocrine-Disruptor Testing Strategy	133
Developmental-Toxicity Testing	133
<i>TABLE 50 OECD CONCEPTUAL FRAMEWORK FOR TESTING ENDOCRINE DISRUPTORS</i>	134
Developmental-Toxicity ... (Continued).....	135
Developmental-Toxicity ... (Continued).....	136
Conclusion.....	137
MARKETS BY INDUSTRY APPLICATIONS: REVENUE FORECASTS	138
MARKETS BY INDUSTRY APPLICATIONS: REVENUE FORECASTS	138
MARKETS BY INDUSTRY: ... (CONTINUED)	139
<i>TABLE 51 U.S. MARKETS FOR IN VITRO TOXICITY TESTING INDUSTRY BY SEGMENT, THROUGH 2011 (\$ MILLION)</i>	140
<i>TABLE 52 U.S. MARKET FORECAST FOR IN VITRO ADME/TOX REVENUE SHARE BY SEGMENT, THROUGH 2011 (\$ MILLIONS)</i>	140
<i>TABLE 53 U.S. IN VITRO TOXICITY TESTING MARKET FORECAST BY TEST CATEGORY IN COSMETICS, THROUGH 214011(\$ MILLION)</i>	140
<i>TABLE 54 SEGMENTATION OF EXPECTED SHARE IN THE IN VITRO TOXICITY MARKETS BY INDUSTRY, 2006 AND 2011 (%)</i>	141
<i>FIGURE 12 SEGMENTATION REVENUE ANALYSIS FOR THE IN VITRO TOXICITY TESTING IN THE PHARMACEUTICAL INDUSTRY, 2006 (%)</i>	141
<i>FIGURE 13 U.S. IN VITRO TESTING MARKET, BY INDUSTRY, 2006 (\$ MILLIONS)</i>	142
GROWTH FACTORS	143
Safety Concerns Are Impelling the Need for Better Modes of Toxicity Testing Measures	143
Paucity of Information on the Dose-Response Relationship.....	143
Guidance from FDA and Other Federal Institutions Further the Adoption Rate.....	144
Faster Turn Around Time Hopes to Improve Adoption Rate of These Enabling Technologies	144
Biomarkers Show Potential for Toxicity Tests	144
INHIBITORS	145
Disincentive toward Sharing Data	145
Limited Data Availability and Experimental Facts Might Slow Market Growth	145
Limited Funding for Validation of Alternative Approaches	145
Attitude of Regulatory Authorities Impedes Growth.....	146
<i>TABLE 55 CRITICAL BARRIERS IMPEDING THE USE OF ALTERNATIVE METHODS</i>	146
<i>TABLE 56 TECHNICAL BARRIERS AND RECOMMENDATIONS</i>	146
<i>TABLE 56 (CONTINUED)</i>	147

<i>TABLE 57 REGULATORY BARRIERS AND RECOMMENDATIONS</i>	147
REGULATORY OVERVIEW	148
REGULATORY OVERVIEW	148
PRINCIPAL CHALLENGES.....	149
FUTURE OPPORTUNITIES	149
INSTITUTIONS THAT IMPACT TOXICITY TESTING MEASURES.....	150
<i>TABLE 58 SOME MAJOR U.S. REGULATORY AGENCIES, PUBLIC-HEALTH</i>	
<i>GOALS, AND RISK-MANAGEMENT APPROACHES</i>	151
AGENCY FOR TOXIC SUBSTANCES AND DISEASE REGISTRY	152
Overview	152
ATSDR and Toxicology	152
CASE STUDIES IN ENVIRONMENTAL MEDICINE (CSEM)	153
Introduction	153
ToxFAQs.....	153
FOOD AND DRUG ADMINISTRATION	153
Overview	153
FDA and Toxicology	154
CIIT CENTERS FOR HEALTH RESEARCH (CIIT)	155
Overview	155
CIIT Centers for Health Research and Toxicology	155
<i>TABLE 59 CIIT MEMBER COMPANIES</i>	156
<i>TABLE 59 (CONTINUED)</i>	157
<i>TABLE 60 CIIT SPONSORS 2005</i>	157
<i>TABLE 60 (CONTINUED)</i>	158
CONSUMER PRODUCTS SAFETY COMMISSION	158
Overview	158
CPSC and Toxicology.....	159
ENVIRONMENTAL PROTECTION AGENCY	159
Overview	159
EPA and Toxicology.....	160
<i>TABLE 61 EPA'S PROGRAMS, PUBLIC HEALTH OBJECTIVES, AND</i>	
<i>EXECUTION FRAMEWORKS</i>	161
ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE	
(HESI).....	162
Overview	162
HESI and Toxicology.....	163
Development of Biomarkers of Toxicity	163
NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH	
SCIENCES (NIEHS).....	163
Overview	163
National Toxicology Program	164
<i>TABLE 62 NOMINATION RATIONALE FOR NTP STUDIES</i>	165
Alternative Testing Approaches	165
Nanotechnology Initiative.....	166

Toxicogenomics	166
Phototoxicity	166
Endocrine Disruptors.....	167
ICCVAM AND NICETAM.....	167
Overview	167
<i>TABLE 63 FEDERAL AGENCIES PARTICIPATING IN ICCVAM</i>	<i>167</i>
<i>TABLE 63 (CONTINUED)</i>	<i>168</i>
<i>TABLE 64 ICCVAM STRATEGIC PRIORITIES.....</i>	<i>168</i>
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC)	169
Overview	169
SCIENTIFIC GROUP ON METHODOLOGIES FOR THE SAFETY EVALUATION OF CHEMICALS (SGOMSEC)	169
TOXICOLOGY DATABASES	170
Exttoxnet	170
HSDB (Hazardous Substances Databank).....	170
TOXLINE	171
IRIS (Integrated Risk Information System).....	171
CCRIS (Chemical Carcinogenesis Research Information System).....	172
Gene-Tox (Genetic Toxicology Data Bank).....	172
ITER (International Toxicity Estimates for Risk)	172
ChemIDplus (Chemical Identification Plus).....	172
DART/ETIC (Developmental and Reproductive Toxicology/ Environmental Teratology Information Center	173
TRI (Toxics Release Inventory)	173
Haz-Map	173
Household Product Database	174
Toxmap	174
DSSTOX (Distributed Structure-Searchable Toxicity Database Network)	175
CPDB (Carcinogenic Potency Database)	175
TETRATOX	176
Acute Toxicity Database	176
<i>TABLE 65 TOXICITY DATABASES.....</i>	<i>177</i>